Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corp. president and CEO Kevin J. McNamara received a direct award of 36,693 stock options on October 20, 2026, with an exercise price of $512.64 per share. The options vest in three equal annual installments beginning October 20, 2027, and expire October 20, 2031. His reported derivative holdings following the grant were 300,851 shares.
CHEMED CORP executive vice president Spencer S. Lee reported exercising stock options for 12,099 shares of capital stock on September 30, 2026, at an exercise price of $445.35 per share. He acquired 12,099 shares of capital stock, while 11,160 shares were delivered or withheld to pay the purchase price and tax obligation on the exercise. He reported 16,097 options following the transaction; those options expire October 28, 2026.
Chemed Corporation president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock on September 28, 2026, at a weighted average price of $513.45 per share. The shares were sold in multiple transactions at prices ranging from $510.93 to $515.12. McNamara directly held 66,418 shares following the sale. No Rule 10b5-1 plan is reported for the sale.
Chemed Corp. vice president and director Thomas C. Hutton exercised stock options to acquire 4,629 shares of capital stock on September 28, 2026, at an exercise price of $445.35 per share. He also reported 4,270 shares delivered or withheld for payment of exercise price or tax liability; his reported resulting position was 22,089 stock options. No Rule 10b5-1 plan is reported.
Chemed Corporation officer Kevin J. McNamara reported a proposed sale of 2,000 common shares, with an aggregate market value of $1,072,260 and an approximate sale date of September 28, 2026. Merrill Lynch is listed as the broker. The notice also lists prior sales of 2,000 shares each on August 3, August 21, and September 17, 2026.
CHEMED CORP (CHE) is identified as issuer in a proposed sale for Kevin J. McNamara, identified as an officer: 2,000 common shares, with an aggregate market value of $998,000 and an approximate sale date of September 18, 2026. Raymond James & Associates, Inc. is listed as broker. Two prior sales are listed under the name Kevin K. McNamara: 2,000 shares on August 21, 2026, for $1,082,324 in gross proceeds, and 2,000 shares on August 3, 2026, for $1,079,023 in gross proceeds.
CHEMED CORP (CHE) reported that president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock on September 18, 2026 in an open-market or private transaction at a weighted average price of $501.40 per share, with individual trade prices ranging from $501.00 to $502.05. Following this sale, he directly holds 68,418 shares of Chemed stock, and no Rule 10b5-1 trading plan is indicated.
CHEMED CORP (CHE) executive vice president Spencer S. Lee reported selling 1,000 shares of CHEMED CORP capital stock on August 21, 2026 in an open-market or private transaction at a price of $541.04 per share. After this sale, Lee directly holds 13,912 shares of CHEMED CORP capital stock.
CHEMED CORP (CHE) reported that president and CEO Kevin J. McNamara sold 2,000 shares of Chemed capital stock on 2026-08-21 in an open market or private transaction. The weighted average sale price was reported as $541.16 per share, with individual trade prices ranging from $539.62 to $542.53. After this transaction, McNamara directly held 70,418 shares of Chemed capital stock. The company notes that full trade-by-trade pricing details are available upon request.
Chemed Corporation (CHE) received a notice under Rule 144 that officer Kevin J. McNamara plans to sell 2,000 shares of common stock through Merrill Lynch on or about 08/21/2026. The shares relate to a stock award and stock exercise dated 02/14/2025. Chemed reports 13,069,961 shares outstanding, a baseline figure, not the amount being sold.